Trial Profile
L-NMMA's Effect on Renal and Cardiovascular Variables in Healthy Subjects. A Randomized, Placebo-controlled Crossover Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tilarginine (Primary)
- Indications Cardiogenic shock; Myocardial infarction
- Focus Pharmacodynamics
- 24 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2010 New trial record